Indivior Pharmaceuticals (INDV) EBIT (2024 - 2026)

Indivior Pharmaceuticals' EBIT history runs 3 years deep, the most recent figure standing at $137.0 million for Q1 2026.

• In Q1 2026, EBIT rose 107.58% year-over-year to $137.0 million; the TTM figure through Mar 2026 stood at $333.0 million (up 1048.28% YoY), while the FY2025 annual figure was $262.0 million, up 589.47% from the prior year.
• EBIT was $137.0 million for Q1 2026 at Indivior Pharmaceuticals, up from $81.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $137.0 million in Q1 2026 to a low of -$118.0 million in Q2 2024.
• Historically, EBIT has averaged $48.6 million across 3 years, with a median of $66.0 million in 2025.
• Biggest YoY gain for EBIT was 161.02% in 2025; the steepest drop was 12.0% in 2025.
• A 3-year view of EBIT shows it stood at $46.0 million in 2024, then surged by 76.09% to $81.0 million in 2025, then surged by 69.14% to $137.0 million in 2026.
• The last three EBIT figures came in at $137.0 million (Q1 2026), $81.0 million (Q4 2025), and $43.0 million (Q3 2025), per Business Quant data.